Ascletis Announces Further Expansion of Ritonavir Oral Tablet Production Capacity to 530 Million Tablets Per Year
HANGZHOU, China and SHAOXING, China, March 13, 2022 /PRNewswire/ — Ascletis Pharma Inc. (Ascletis, HKEX: 1672) today announces that it has further expanded its ritonavir oral tablet production capacity to approximately 530 million tablets per year, to meet the potential escalation in the…
Comments Off on Ascletis Announces Further Expansion of Ritonavir Oral Tablet Production Capacity to 530 Million Tablets Per Year